Boston Scientific (BSX) · Medical Devices
Boston Scientific Q2 2026 earnings: summary, key numbers & outlook
Results filed 29 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Boston Scientific bought into transcatheter aortic valves through a $1.5 billion MiRus stake while FARAPULSE and WATCHMAN faced share and referral pressure in the U.S.
Boston Scientific made a strategic move into transcatheter aortic valve replacement (TAVR) by investing $1.5 billion in MiRus for about 34% of the company and an exclusive option to buy its TAVR business. Clinical data advanced across the pipeline: FARAPULSE beat anti-arrhythmic drugs in persistent atrial fibrillation, and the SEISMIQ 4CE lithotripsy catheter met its primary endpoints. Growth was strongest in Neuromodulation, while Urology was nearly flat.
Management is steering toward new franchises, including TAVR, next-generation PFA catheters and coronary lithotripsy, and toward cost savings. The main tension is that the U.S. WATCHMAN market slowed sharply and PFA competitors are taking share faster than management expected. The company has lowered its outlook, and the new products must offset pressure in two core franchises.
No call transcript for this quarter, so this summary also draws on: Webull (Motley Fool transcript) ↗.
Key numbers
- Net sales · GAAP
- $5.442 billion
- Net income attributable to common stockholders · GAAP
- $907 million
- Diluted EPS · GAAP
- $0.61
- Adjusted EPS · non-GAAP
- $0.86
- Operating income · GAAP
- $1.2B
up 7.5% reported and 7.0% organic from a year ago
vs. $797 million a year ago
vs. $0.53 a year ago
vs. $0.75 a year ago
vs. $819 million a year ago
| Segment or metric | Value | Change |
|---|---|---|
| MedSurg | $1.8B | up 5.9% reported, 5.4% organic |
| Endoscopy | $793.0M | up 7.6% reported, 7.0% organic |
| Urology | $684.0M | up 1.1% reported, 0.8% organic |
| Neuromodulation | $341.0M | up 12.7% reported, 12.2% organic |
| United States | $3.4B | up 6.2% reported and operational |
| Asia-Pacific | $878.0M | up 11.2% reported and operational |
| Latin America and Canada | $206.0M | up 22.4% reported, 16.2% operational |
Where each number comes from
- Net sales: “Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis”
- Net income attributable to common stockholders: “GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago”
- Diluted EPS: “GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago”
- Adjusted EPS: “achieved adjusted3 EPS of $0.86 for the period, compared to $0.75 a year ago”
- Operating income: “Reported | $3,848 | $2,670 | $1,178 | $(118) | $1,060 | $905 | $(2) | $907 | $0.61”
- MedSurg: “MedSurg | 1,818 | 1,716 | 5.9% | (0.5)% | 5.4% | —% | 5.4%”
- Endoscopy: “Endoscopy | $793 | $737 | 7.6% | (0.7)% | 7.0% | —% | 7.0%”
- Urology: “Urology | 684 | 676 | 1.1% | (0.3)% | 0.8% | —% | 0.8%”
- Neuromodulation: “Neuromodulation | 341 | 303 | 12.7% | (0.6)% | 12.2% | —% | 12.2%”
- United States: “U.S. | $3,426 | $3,224 | 6.2% | —% | 6.2% EMEA | 932 | 878 | 6.1% | (1.9)% | 4.2%”
- Asia-Pacific: “APAC | 878 | 790 | 11.2% | (0.0)% | 11.2% LACA | 206 | 169 | 22.4% | (6.2)% | 16.2%”
- Latin America and Canada: “APAC | 878 | 790 | 11.2% | (0.0)% | 11.2% LACA | 206 | 169 | 22.4% | (6.2)% | 16.2%”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $5.4B | +7.5% | +4.6% |
| Operating income | $1.2B | +43.8% | +7.0% |
| Net income | $905.0M | +13.8% | −32.4% |
| Diluted EPS | $0.61 | +15.1% | −32.2% |
| Free cash flow | $1.3B | +13.3% | +648.0% |
| Gross margin | 70.7% | +3.0 pts | +1.2 pts |
| Operating margin | 21.6% | +5.4 pts | +0.4 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Net sales growth (reported and organic) | third quarter of 2026 | 3 to 5 percent |
| Adjusted EPS | third quarter of 2026 | $0.80 to $0.82 |
| Net sales growth (reported) | full year 2026 | 5.5 to 6.5 percent |
| Net sales growth (organic) | full year 2026 | 5 to 6 percent |
| Adjusted EPS | full year 2026 | $3.28 to $3.32 |
Key takeaways
MiRus stake gives Boston Scientific a TAVR path
Boston Scientific invested $1.5 billion in MiRus for about 34% equity and an exclusive option to acquire its TAVR business. The SIEGEL balloon-expandable valve is investigational and not available for sale.
FARAPULSE showed superiority over drugs in persistent AF
The AVANT GUARD study met all safety and effectiveness endpoints and showed statistical superiority over anti-arrhythmic drugs in previously untreated persistent AF. That supports using PFA earlier in the treatment path.
Next-generation PFA catheter advances into a pivotal trial
Early ELEVATE-PF data for the FARAFLEX map-and-ablate catheter showed strong lesion durability and no reported pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke. The pivotal FARADIGM trial has begun enrolling, as management faces PFA competition.
U.S. PFA competition is taking share
Management said it remains the PFA leader but its share has come down, and it had not anticipated the competitive share movement it is now seeing. U.S. PFA is now roughly 80% of the AFib market, so the pressure lands in a core franchise.
WATCHMAN slowed as clinical evidence shifted referrals
Management said the U.S. WATCHMAN market slowed sharply and unexpectedly, driven by compounding clinical evidence that changed referral patterns. It estimates about one-third of U.S. WATCHMAN procedures are now done together with another procedure.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $4.6B * |
| Q1 2025 | $4.7B |
| Q2 2025 | $5.1B |
| Q3 2025 | $5.1B |
| Q4 2025 | $5.3B * |
| Q1 2026 | $5.2B |
| Q2 2026 | $5.4B |
| Q3 2026 | $5.1B |
Data
| Q1 2025 | $0.45 |
| Q2 2025 | $0.53 |
| Q3 2025 | $0.51 |
| Q1 2026 | $0.90 |
| Q2 2026 | $0.61 |
| Q3 2026 | $0.40 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 14.8% |
| Q1 2025 | 19.8% |
| Q2 2025 | 16.2% |
| Q3 2025 | 20.7% |
| Q4 2025 | 15.6% |
| Q1 2026 | 21.2% |
| Q2 2026 | 21.6% |
| Q3 2026 | 16.1% |
Data
| Q4 2024 | $1.2B |
| Q1 2025 | $354.0M |
| Q2 2025 | $1.1B |
| Q3 2025 | $1.2B |
| Q4 2025 | $1.0B |
| Q1 2026 | $171.0M |
| Q2 2026 | $1.3B |
| Q3 2026 | $868.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What is Boston Scientific's MiRus deal?
Boston Scientific invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire the MiRus TAVR business. MiRus's SIEGEL balloon-expandable TAVR system is investigational.
What clinical data did Boston Scientific report for FARAPULSE and its next PFA catheter?
AVANT GUARD showed FARAPULSE was statistically superior to anti-arrhythmic drugs in previously untreated persistent AF. The FARAFLEX catheter showed strong lesion durability in ELEVATE-PF, and its pivotal FARADIGM trial has started enrolling.
What is happening with WATCHMAN in the U.S.?
Management said the U.S. market slowed sharply and unexpectedly, driven by clinical evidence that changed referral patterns. About one-third of U.S. WATCHMAN procedures are now done concomitantly.
How is competition affecting Boston Scientific's PFA business?
Management said it remains the PFA leader but its U.S. share has come down, and it did not anticipate the degree of competitive share movement. U.S. PFA now makes up roughly 80% of the AFib market.
What new products are coming to market?
The SEISMIQ 4CE coronary lithotripsy catheter met its primary endpoints in the FRACTURE trial, and management expects to bring it to market in the first half of 2027. The company also received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter.
Documents
SEC filing